Printer Friendly

PHARMACEUTICAL EXECUTIVE MAX LINK ELECTED DIRECTOR OF PROTEIN DESIGN LABS

 MOUNTAIN VIEW, Calif., June 15 /PRNewswire/ -- Protein Design Labs Inc. (PDL)(NASDAQ: PDLI) said today that senior pharmaceutical industry executive Max Link has been elected a director of the company.
 Link, 53, in May became chief executive officer of Corange Ltd., the London-based private health care company, which encompasses the Boehringer Mannheim and DePuy brands of products. He resigned as chairman of Sandoz Pharma Ltd., the pharmaceutical unit of Sandoz Ltd., effective June 30, 1993.
 He was elected to the PDL board yesterday at a regularly scheduled board meeting. Other PDL directors are Laurence Jay Korn, Ph.D., president, chief executive officer and chairperson, PDL; Cary L. Queen, Ph.D., vice president, Research, PDL; Stanley Falkow, Ph.D., professor of microbiology and medicine, Stanford University School of Medicine; George M. Gould, vice president, Licensing and Corporate Development, Hoffmann-La Roche Inc.; and Jon S. Saxe, president, Saxe Associates Inc. With the election of Link four of the six board members are outside directors.
 Link has been chairman of Sandoz Pharma since 1992 and was chief executive officer from 1990 to 1992. Prior to this, he was head of the Pharmaceutical Division and member of the executive board of Sandoz Ltd. From 1978 to 1987 he held a number of senior positions in Sandoz's U.S. operations, including president and chief executive officer of Sandoz Corp. (1985-1987), head of the Pharmaceutical Division of Sandoz Inc. (1981-1985) and head of Finance of Sandoz Inc. (1978-1981). Link heads the Economic Policy Committee of the European Federation Pharmaceutical Industry Association (EFPIA). A Swiss national, he has a Ph.D. in economics from St. Gallen University.
 Protein Design Labs, founded in 1986, is engaged in the development of next-generation antibodies and other novel proteins to treat various disease conditions, including viral infections, autoimmune and inflammatory diseases and cancer.
 The company has four potential products in clinical trials and two core proprietary antibody technologies. PDL uses computer modeling techniques to combine the binding site of a mouse antibody with a large part of a human antibody. The resulting SMART Antibodies, which are more than 90-percent human, retain high binding affinity for the target antigens and will, PDL believes, substantially reduce or avoid the human anti-mouse antibody (HAMA) response that has limited the use of mouse monoclonal antibodies as human therapeutics. Two SMART Antibodies are in clinical trials.
 PDL's second antibody technology is for development of human antibodies against viruses. This technology, as well as four human anti-viral antibodies developed with the technology, were acquired from Sandoz Pharmaceuticals Corp. and Sandoz Pharma Ltd. in April. Two of the human antibodies are in clinical trials.
 -0- 6/15/93
 /CONTACT: Peter Dworkin, director of corporate communications for Protein Design Labs, 415-903-3721/
 (PDLI)


CO: Protein Design Labs Inc. ST: California IN: MTC SU: PER

SG-TM -- SJ002 -- 1908 06/15/93 07:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 15, 1993
Words:473
Previous Article:ALDUS SHIPS PAGEMAKER 5.0 FOR WINDOWS
Next Article:MCDERMOTT INTERNATIONAL BOARD VOTES TO DECLARE DIVIDENDS
Topics:


Related Articles
BRENT LARSEN NAMED DIRECTOR, PROCESS DEVELOPMENT FOR PROTEIN DESIGN LABS
PROTEIN DESIGN LABS HIRES VETERAN BUSINESS JOURNALIST FOR COMMUNICATIONS POST
DEVELOPER OF HUMAN ANTIBODIES JOINS PROTEIN DESIGN LABS
PROTEIN DESIGN LABS APPOINTS JAMES CORNETT DIRECTOR, BUSINESS DEVELOPMENT
Protein Design Labs Announces Agreement With Fujisawa.
Protein Design Labs to Humanize Antibody for Fujisawa.
Protein Design Labs to Humanize Antibody for Lilly.
Brett Schmidli Joins Protein Design Labs as Senior Vice President, Technical Operations.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters